Amarin Receives National Reimbursement for VAZKEPA® in Austria

Core Insights - Austrian Health Authorities have approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular event risks in eligible patients, effective April 1, 2025, marking the 10th national reimbursement approval in Europe for this product [1][4]. Group 1: Company Overview - Amarin Corporation is an innovative pharmaceutical company focused on cardiovascular disease management, with a commitment to advancing treatment options for patients worldwide [5]. - The company has offices in multiple locations, including Bridgewater, New Jersey, Dublin, Ireland, and Zug, Switzerland, and collaborates with commercial partners globally [5]. Group 2: Industry Context - Cardiovascular diseases accounted for approximately 35% of all deaths in Austria in 2023, highlighting the urgent need for effective treatment options [2]. - More than 100,000 hospitalizations in Austria in 2023 were due to cardiovascular diseases, with direct and indirect costs estimated at around 4.7 billion euros in 2015 [2]. Group 3: Reimbursement Impact - The reimbursement of VAZKEPA® is seen as a significant advancement in addressing the unmet needs of patients with established cardiovascular disease whose triglycerides remain elevated despite statin treatment [3]. - This decision is expected to alleviate the burden on the healthcare system and improve patient outcomes in secondary prevention of cardiovascular diseases [3].